{"nctId":"NCT00250679","briefTitle":"Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","startDateStruct":{"date":"2005-10"},"conditions":["Chronic Obstructive Pulmonary Disease","Bronchitis","Emphysema"],"count":443,"armGroups":[{"label":"Formoterol 12 ųg 2x/day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol 12 ųg BID","Drug: Placebo"]},{"label":"Arformoterol 15 ųg 2x/day","type":"EXPERIMENTAL","interventionNames":["Drug: Arformoterol tartrate inhalation solution","Drug: Placebo"]},{"label":"Arformoterol 25 ųg 2x/day","type":"EXPERIMENTAL","interventionNames":["Drug: Arformoterol 25 ųg BID","Drug: Placebo"]}],"interventions":[{"name":"Arformoterol tartrate inhalation solution","otherNames":["Brovana®"]},{"name":"Arformoterol 25 ųg BID","otherNames":["Brovana","R,R formoterol"]},{"name":"Formoterol 12 ųg BID","otherNames":["Foradil","R,S-formoterol"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male and female subjects must be at least 35 years old at the time of consent\n* Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD\n* Subjects must have a \\>=15 pack-year smoking history and a baseline breathlessness severity grade of \\>=2 (Modified Medical Research Council \\[MMRC\\] Dyspnea Scale Score) at Visits 1 and 2\n* Female subjects \\<=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control\n* Subjects must be in general good health.\n\nKey Exclusion criteria:\n\n* Subjects with a history of asthma, with the exception of asthma diagnosed in childhood\n* Subjects with a blood eosinophil count \\>5% of total white blood cell count\n* Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1\n* Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations","description":"Percent of participants with the adverse event specified.\n\nSOC = system organ class.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"67.8","spread":null},{"groupId":"OG002","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"13.4","spread":null},{"groupId":"OG002","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"10.7","spread":null},{"groupId":"OG002","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"6.0","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"13.4","spread":null},{"groupId":"OG002","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"32.2","spread":null},{"groupId":"OG002","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":null},{"groupId":"OG001","value":"35.6","spread":null},{"groupId":"OG002","value":"38.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"34.2","spread":null},{"groupId":"OG002","value":"34.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New 24-Hour Holter Monitoring Alerts","description":"New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Potentially Clinically Significant Glucose Evaluations","description":"Patients with glucose values that met low (\\<=40 mg/dL) or high (\\>=175 mg/dL) criteria were considered potentially clinically significant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Potentially Clinically Significant Potassium Evaluations","description":"Patients with potassium values that met low (\\<=3 mEq/L) or high (\\>=6 mEq/L) criteria were considered potentially clinically significant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts","description":"New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity Changes From Baseline","description":"Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.240","spread":"0.363"},{"groupId":"OG001","value":"0.297","spread":"0.300"},{"groupId":"OG002","value":"0.330","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","spread":"0.380"},{"groupId":"OG001","value":"0.032","spread":"0.409"},{"groupId":"OG002","value":"0.124","spread":"0.370"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.206","spread":"0.410"},{"groupId":"OG001","value":"0.241","spread":"0.401"},{"groupId":"OG002","value":"0.331","spread":"0.448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.114","spread":"0.368"},{"groupId":"OG001","value":"0.005","spread":"0.441"},{"groupId":"OG002","value":"0.124","spread":"0.447"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.290","spread":"0.445"},{"groupId":"OG001","value":"0.233","spread":"0.364"},{"groupId":"OG002","value":"0.284","spread":"0.423"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.039","spread":"0.354"},{"groupId":"OG001","value":"0.057","spread":"0.326"},{"groupId":"OG002","value":"0.154","spread":"0.371"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.234","spread":"0.451"},{"groupId":"OG001","value":"0.202","spread":"0.402"},{"groupId":"OG002","value":"0.368","spread":"0.443"}]}]}]},{"type":"SECONDARY","title":"6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)","description":"The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.294","spread":"0.210"},{"groupId":"OG001","value":"0.314","spread":"0.189"},{"groupId":"OG002","value":"0.357","spread":"0.218"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.280","spread":"0.229"},{"groupId":"OG001","value":"0.305","spread":"0.211"},{"groupId":"OG002","value":"0.334","spread":"0.230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.251","spread":"0.223"},{"groupId":"OG001","value":"0.316","spread":"0.236"},{"groupId":"OG002","value":"0.323","spread":"0.222"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.264","spread":"0.230"},{"groupId":"OG001","value":"0.302","spread":"0.239"},{"groupId":"OG002","value":"0.343","spread":"0.224"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Potentially Clinically Significant Heart Rate","description":"Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week","description":"Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":"2.92"},{"groupId":"OG001","value":"3.73","spread":"2.95"},{"groupId":"OG002","value":"3.84","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":"2.63"},{"groupId":"OG001","value":"2.36","spread":"2.60"},{"groupId":"OG002","value":"2.52","spread":"2.66"}]}]}]},{"type":"SECONDARY","title":"Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day","description":"Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"2.72"},{"groupId":"OG001","value":"2.43","spread":"2.69"},{"groupId":"OG002","value":"2.67","spread":"3.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"2.28"},{"groupId":"OG001","value":"1.59","spread":"2.37"},{"groupId":"OG002","value":"1.58","spread":"2.12"}]}]}]},{"type":"SECONDARY","title":"Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week","description":"Rescue medication usage during the study. MDI stands for metered dose inhaler.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":"2.85"},{"groupId":"OG001","value":"4.20","spread":"2.86"},{"groupId":"OG002","value":"4.23","spread":"2.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"2.64"},{"groupId":"OG001","value":"2.44","spread":"2.49"},{"groupId":"OG002","value":"2.75","spread":"2.64"}]}]}]},{"type":"SECONDARY","title":"Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day","description":"Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"2.80"},{"groupId":"OG001","value":"2.68","spread":"2.57"},{"groupId":"OG002","value":"2.97","spread":"3.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"2.27"},{"groupId":"OG001","value":"1.56","spread":"2.32"},{"groupId":"OG002","value":"1.65","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline","description":"Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.191","spread":"0.172"},{"groupId":"OG001","value":"0.216","spread":"0.157"},{"groupId":"OG002","value":"0.253","spread":"0.179"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.175","spread":"0.204"},{"groupId":"OG001","value":"0.208","spread":"0.200"},{"groupId":"OG002","value":"0.224","spread":"0.206"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.155","spread":"0.210"},{"groupId":"OG001","value":"0.214","spread":"0.225"},{"groupId":"OG002","value":"0.218","spread":"0.214"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.161","spread":"0.209"},{"groupId":"OG001","value":"0.197","spread":"0.229"},{"groupId":"OG002","value":"0.241","spread":"0.209"}]}]}]},{"type":"SECONDARY","title":"Transitional (Relative Change in) Dyspnea Index","description":"The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"2.40"},{"groupId":"OG001","value":"1.47","spread":"2.56"},{"groupId":"OG002","value":"1.56","spread":"2.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"2.77"},{"groupId":"OG001","value":"1.43","spread":"2.83"},{"groupId":"OG002","value":"1.49","spread":"2.76"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Improved Transitional Dyspnea Index","description":"The number of participants with a transitional focal score (range -9 to 9) of \\>=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)","description":"The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.162","spread":"0.209"},{"groupId":"OG001","value":"0.172","spread":"0.206"},{"groupId":"OG002","value":"0.155","spread":"0.226"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.096","spread":"0.192"},{"groupId":"OG001","value":"0.124","spread":"0.209"},{"groupId":"OG002","value":"0.131","spread":"0.201"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.094","spread":"0.192"},{"groupId":"OG001","value":"0.116","spread":"0.187"},{"groupId":"OG002","value":"0.101","spread":"0.207"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.087","spread":"0.215"},{"groupId":"OG001","value":"0.098","spread":"0.243"},{"groupId":"OG002","value":"0.137","spread":"0.229"}]}]}]},{"type":"SECONDARY","title":"Subject Global Evaluations Change From Baseline","description":"The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"1.39"},{"groupId":"OG001","value":"-1.11","spread":"1.51"},{"groupId":"OG002","value":"-0.89","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"1.50"},{"groupId":"OG001","value":"-1.06","spread":"1.41"},{"groupId":"OG002","value":"-0.83","spread":"1.70"}]}]}]},{"type":"SECONDARY","title":"Investigator Global Evaluations Change From Baseline","description":"The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"1.27"},{"groupId":"OG001","value":"-0.88","spread":"1.27"},{"groupId":"OG002","value":"-0.75","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"1.20"},{"groupId":"OG001","value":"-0.74","spread":"1.28"},{"groupId":"OG002","value":"-0.76","spread":"1.65"}]}]}]},{"type":"SECONDARY","title":"BODE Index","description":"The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.82","spread":"1.58"},{"groupId":"OG001","value":"4.98","spread":"1.64"},{"groupId":"OG002","value":"5.14","spread":"1.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"2.03"},{"groupId":"OG001","value":"3.97","spread":"1.90"},{"groupId":"OG002","value":"4.28","spread":"1.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":"1.91"},{"groupId":"OG001","value":"3.94","spread":"1.99"},{"groupId":"OG002","value":"4.11","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes","description":"Mean change from baseline in distance walked (meters)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.28","spread":"81.22"},{"groupId":"OG001","value":"15.72","spread":"67.59"},{"groupId":"OG002","value":"12.37","spread":"69.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.05","spread":"104.90"},{"groupId":"OG001","value":"4.13","spread":"128.01"},{"groupId":"OG002","value":"31.07","spread":"77.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.42","spread":"94.19"},{"groupId":"OG001","value":"1.24","spread":"135.05"},{"groupId":"OG002","value":"37.00","spread":"85.01"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in St. George's Respiratory Questionnaire","description":"Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.16","spread":"10.09"},{"groupId":"OG001","value":"-3.44","spread":"12.10"},{"groupId":"OG002","value":"-1.92","spread":"9.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.76","spread":"10.06"},{"groupId":"OG001","value":"-3.73","spread":"13.14"},{"groupId":"OG002","value":"-3.68","spread":"11.78"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a >=4 Unit Improvement on the St. George's Respiratory Questionnaire","description":"Scores are expressed as the number of participants with \\>= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Modified Medical Research Council Dyspnea Questionaire","description":"Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":"0.78"},{"groupId":"OG001","value":"2.76","spread":"0.79"},{"groupId":"OG002","value":"2.91","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":"1.02"},{"groupId":"OG001","value":"2.47","spread":"0.96"},{"groupId":"OG002","value":"2.50","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"1.03"},{"groupId":"OG001","value":"2.10","spread":"1.05"},{"groupId":"OG002","value":"2.43","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"1.10"},{"groupId":"OG001","value":"2.09","spread":"1.14"},{"groupId":"OG002","value":"2.26","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Percent (%) of Participants With an Improved Transitional Dyspnea Index","description":"The percentage of participants with a transitional focal score (range -9 to 9) of \\>=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"52.2","spread":null},{"groupId":"OG002","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"48.0","spread":null},{"groupId":"OG002","value":"52.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent (%) of Participants With a >=4 Unit Improvement in the St. George's Respiratory Questionaire","description":"Percent of participants with a \\>=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"46.1","spread":null},{"groupId":"OG002","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Values for the 6-Minute Walk Test: Distance Walked in Meters","description":"This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334.84","spread":"155.43"},{"groupId":"OG001","value":"315.94","spread":"131.74"},{"groupId":"OG002","value":"328.36","spread":"183.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352.19","spread":"163.27"},{"groupId":"OG001","value":"332.80","spread":"135.79"},{"groupId":"OG002","value":"339.81","spread":"194.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344.95","spread":"175.53"},{"groupId":"OG001","value":"332.25","spread":"140.60"},{"groupId":"OG002","value":"333.63","spread":"150.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352.51","spread":"167.90"},{"groupId":"OG001","value":"337.28","spread":"165.02"},{"groupId":"OG002","value":"337.68","spread":"155.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"355.83","spread":"181.84"},{"groupId":"OG001","value":"338.21","spread":"129.68"},{"groupId":"OG002","value":"337.25","spread":"167.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361.72","spread":"169.96"},{"groupId":"OG001","value":"344.98","spread":"122.38"},{"groupId":"OG002","value":"348.11","spread":"174.38"}]}]}]},{"type":"SECONDARY","title":"Mean Values for Investigator Global Evaluations","description":"The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":"0.88"},{"groupId":"OG001","value":"3.88","spread":"0.77"},{"groupId":"OG002","value":"3.84","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.12","spread":"1.05"},{"groupId":"OG001","value":"3.04","spread":"1.17"},{"groupId":"OG002","value":"3.04","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.08","spread":"1.04"},{"groupId":"OG001","value":"3.16","spread":"1.28"},{"groupId":"OG002","value":"3.01","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Mean Values for St. George's Respiratory Questionnaire","description":"A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.86","spread":"14.90"},{"groupId":"OG001","value":"49.36","spread":"17.38"},{"groupId":"OG002","value":"52.40","spread":"17.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.48","spread":"16.53"},{"groupId":"OG001","value":"43.64","spread":"18.94"},{"groupId":"OG002","value":"49.95","spread":"19.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.72","spread":"16.35"},{"groupId":"OG001","value":"42.69","spread":"17.98"},{"groupId":"OG002","value":"48.09","spread":"20.68"}]}]}]},{"type":"SECONDARY","title":"Mean Values for Subject Global Evaluations","description":"The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":"1.08"},{"groupId":"OG001","value":"3.97","spread":"1.08"},{"groupId":"OG002","value":"3.86","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":"1.09"},{"groupId":"OG001","value":"2.88","spread":"1.26"},{"groupId":"OG002","value":"2.94","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":"1.31"},{"groupId":"OG001","value":"2.96","spread":"1.32"},{"groupId":"OG002","value":"2.94","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Mean Values for Inspiratory Capacity","description":"Inspiratory capacity is the maximum volume that can be inhaled.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.739","spread":"0.630"},{"groupId":"OG001","value":"1.864","spread":"0.551"},{"groupId":"OG002","value":"1.764","spread":"0.577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.826","spread":"0.654"},{"groupId":"OG001","value":"1.889","spread":"0.558"},{"groupId":"OG002","value":"1.909","spread":"0.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.874","spread":"0.676"},{"groupId":"OG001","value":"1.890","spread":"0.656"},{"groupId":"OG002","value":"1.962","spread":"0.640"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.817","spread":"0.620"},{"groupId":"OG001","value":"1.901","spread":"0.630"},{"groupId":"OG002","value":"2.070","spread":"0.691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.976","spread":"0.730"},{"groupId":"OG001","value":"2.161","spread":"0.624"},{"groupId":"OG002","value":"2.109","spread":"0.610"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.973","spread":"0.685"},{"groupId":"OG001","value":"2.111","spread":"0.627"},{"groupId":"OG002","value":"2.108","spread":"0.632"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.089","spread":"0.729"},{"groupId":"OG001","value":"2.081","spread":"0.658"},{"groupId":"OG002","value":"2.176","spread":"0.692"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.978","spread":"0.690"},{"groupId":"OG001","value":"2.084","spread":"0.613"},{"groupId":"OG002","value":"2.273","spread":"0.692"}]}]}]},{"type":"SECONDARY","title":"Mean Values for Forced Expiratory Volume in One Second (FEV1)","description":"Forced Expiratory Volume in one second","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.210","spread":"0.420"},{"groupId":"OG001","value":"1.222","spread":"0.465"},{"groupId":"OG002","value":"1.204","spread":"0.422"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.378","spread":"0.497"},{"groupId":"OG001","value":"1.400","spread":"0.545"},{"groupId":"OG002","value":"1.360","spread":"0.470"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.311","spread":"0.458"},{"groupId":"OG001","value":"1.323","spread":"0.484"},{"groupId":"OG002","value":"1.327","spread":"0.477"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.310","spread":"0.456"},{"groupId":"OG001","value":"1.346","spread":"0.490"},{"groupId":"OG002","value":"1.355","spread":"0.475"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.281","spread":"0.470"},{"groupId":"OG001","value":"1.310","spread":"0.483"},{"groupId":"OG002","value":"1.308","spread":"0.473"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.316","spread":"0.461"},{"groupId":"OG001","value":"1.331","spread":"0.460"},{"groupId":"OG002","value":"1.294","spread":"0.444"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.283","spread":"0.466"},{"groupId":"OG001","value":"1.291","spread":"0.453"},{"groupId":"OG002","value":"1.325","spread":"0.451"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.296","spread":"0.455"},{"groupId":"OG001","value":"1.314","spread":"0.467"},{"groupId":"OG002","value":"1.360","spread":"0.468"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.383","spread":"0.511"},{"groupId":"OG001","value":"1.410","spread":"0.533"},{"groupId":"OG002","value":"1.428","spread":"0.479"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.338","spread":"0.464"},{"groupId":"OG001","value":"1.386","spread":"0.504"},{"groupId":"OG002","value":"1.386","spread":"0.484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.339","spread":"0.487"},{"groupId":"OG001","value":"1.385","spread":"0.482"},{"groupId":"OG002","value":"1.361","spread":"0.463"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.310","spread":"0.475"},{"groupId":"OG001","value":"1.355","spread":"0.457"},{"groupId":"OG002","value":"1.384","spread":"0.483"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Bronchitis","Headache","Muscle spasms"]}}}